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Mesalazine pharmacokinetics and NAT2 phenotype
Abstract
BACKGROUND: Mesalazine undergoes extensive metabolism by N-acetylation. While there is some
evidence for an involvement of N-acetyltransferase (NAT) type 1, a potential role of NAT type 2
(NAT2) in vivo has not been tested. METHODS: In two studies in healthy young Caucasians, NAT2
phenotyping was carried out using a caffeine metabolic ratio in urine 4-6 h postdose. In study A, 1,000
mg mesalazine doses were given thrice daily for 5 days, and urine and blood samples were drawn during
the last dosing interval. In study B, a 1,000 mg single dose was given, and samples were taken for 48 h
postdose. Pharmacokinetics of mesalazine and N-acetylmesalazine (LC-MS/MS) were calculated by
noncompartmental methods. RESULTS: NAT2 phenotype could be allocated unequivocally in 21 slow
and 5 rapid acetylators in study A, and in 9 slow and 8 rapid acetylators in study B. Geometric mean
(CV%) values in study A for slow [rapid] acetylators were as follows: mesalazine AUC 11.1
microg/mL.h (51%) [12.0 microg/mL.h (52%)], N-acetylmesalazine AUC 27.7 microg/mL.h (32%)
[30.5 microg/mL.h (27%)], mesalazine Ae 8.53% (89%) [9.03% (52%)], N-acetylmesalazine Ae 31.4%
(46%) [32.2 (41%)]. Values in study B were as follows: mesalazine AUC 3.45 microg/mL.h (113%)
[2.36 microg/mL.h (87%)], N-acetylmesalazine AUC 21.3 microg/mL.h (29%) [18.0 microg/mL.h
(39%)], mesalazine Ae 0.2% (256%) [0.1% (359%)], N-acetylmesalazine Ae 30.9% (44%) [18.1%
(84%)]. Higher AUC and Ae values for mesalazine in steady state study indicate saturation of
mesalazine metabolism. Statistics provided no evidence for a true difference in mesalazine
pharmacokinetics between slow and rapid acetylators, and no significant correlation between NAT2
activity and any mesalazine pharmacokinetic parameter was found. CONCLUSION: NAT2 has no
major role in human metabolism of mesalazine in vivo.
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ABSTRACT 
 
Background: Mesalazine undergoes extensive metabolism by N-acetylation. While there is 
some evidence for an involvement of N-acetyltransferase (NAT) type 1, a potential role of 
NAT type 2 (NAT2) in vivo has not been tested.  
Methods: In two studies in healthy young Caucasians, NAT2 phenotyping was carried out 
using a caffeine metabolic ratio in urine 4- 6 hours postdose. In study A, 1000 mg mesalazine 
dosis was given thrice daily for 5 days, and urine and blood samples were drawn in the last 
dosing interval. In study B, a 1000 mg single dose was given, and samples were taken until 48 
hours postdose. Pharmacokinetics of mesalazine and N-acetylmesalazine (LC-MS/MS) were 
calculated by noncompartmental methods.  
Results: NAT2 phenotype could be allocated unequivocally in 21 slow and 5 rapid 
acetylators in study A and in 9 slow / 8 rapid acetylators in study B. Geometric mean [CV%] 
values in study A for slow (rapid) acetylators were: mesalazine AUC 11.1 [51 %] (12.0 [52 
%]) µg/mL*h; N-acetylmesalazine AUC 27.7 [32 %] (30.5 [27 %]) µg/mL*h; mesalazine Ae 
8.53 [89 %] (9.03 [52 %]) %; N-acetylmesalazine Ae 31.4 [46 %] (32.2 [41 %]) %. Values in 
study B were: mesalazine AUC 3.45 [113 %] (2.36 [87 %]) µg/mL*h; N-acetylmesalazine 
AUC 21.3 [29 %] (18.0 [39 %]) µg/mL*h; mesalazine Ae 0.2 [256 %] (0.1 [359 %]) %; N-
acetylmesalazine Ae 30.9 [44 %] (18.1 [84 %]) %. Higher AUC and Ae values for mesalazine 
in steady state study indicate saturation of mesalazine metabolism. Statistics provided no 
evidence for a true difference in mesalazine pharmacokinetics between slow and rapid 
acetylators, and no significant correlation between NAT2 activity and any mesalazine 
pharmacokinetic parameter was found.  
Conclusion: NAT2 has no major role in human metabolism of mesalazine in vivo.  
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INTRODUCTION 
 
Mesalazine is an anti-inflammatory drug mainly used in the treatment of ulcerative colitis but 
also with some value in Crohn’s disease . It undergoes extensive metabolism by N-acetylation 
[1]. On an average, concentrations of N-acetylmesalazine in plasma and N-acetylmesalazine 
amounts excreted in urine exceed those of the parent compound more than twofold. Two 
enzymes are known to primarily mediate N-acetylation in humans, i.e. N-acetyltransferase 
type 1 (NAT1) and type 2 (NAT2). However, currently it is not clear which enzyme plays the 
key role in N-acetylation of mesalazine. In the mouse (which has 3 NATs), all NATs were 
able to metabolize mesalazine in vitro, while murine NAT2 had the highest activity [2]. In an 
in vitro study with human enzymes, both NAT1 and NAT2 were able to mediate 4-
aminosalicylic acid N-acetylation (mesalazine is 5-aminosalicylic acid), with NAT1 having a 
131-fold higher intrinsic clearance than NAT2 [3].  
 
Both human enzymes are expressed at high levels in the human intestine and in the liver [4]. 
N-acetylation of mesalazine is highly variable [5]. As both human NATs have genetic 
polymorphisms, this finding provides no information on the identity of the enzyme. In one 
study, pharmacokinetics of mesalazine and sulfapyridine, the two bacterial metabolites of 
sulfasalazine formed by reductive cleavage of the azo bond linking these two components, 
were determined. While acetylation of sulfapyridine, a known NAT2 substrate, was 
polymorphic, this could not be shown for mesalazine [6]. Mesalazine pharmacokinetics did 
also not co-segregate with NAT2 activity as assessed by sulfadimidine, but the respective 
study was conducted in 6 subjects only [7]. Furthermore, under saturation conditions for 
mesalazine, no relationship of ex vivo mucosal N-acetylation of mesalazine to systemic N-
acetylation of sulfapyridine following systemic administration of sulfasalazine was found [8]. 
On the other hand, in two studies there was also no difference with regard to mesalazine 
tolerability and therapeutic response between NAT1 genotypes [9, 10].  
 
 
Lück et al: Mesalazine and NAT2 page 4 
 
In summary, current evidence for a major role of NAT1 in acetylation of mesalazine in vivo is 
partially contradictory, and the evidence suggesting that NAT2 has no major role originates 
from studies with relevant methodological limitations. Thus, the objective of the present 
evaluation is to assess the role of NAT2 in the N-acetylation of mesalazine in humans in vivo 
by comparison of mesalazine pharmacokinetics to NAT2 phenotype based on a validated 
caffeine-based NAT2 metric.  
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Volunteers and Methods 
 
A total number of 28 and 18 young female and male Caucasian volunteers were included in 
two separate studies A and B, respectively (Table 1). The studies were approved by the Ethics 
Committee of the University of Cologne. Each study participant provided written informed 
consent prior to inclusion in the study. Participants were considered to be healthy based on a 
screening examination including physical examination, medical history, vital signs, ECG 
recording, clinical chemistry tests, urinalysis, and test on drugs of abuse and alcohol. 
Smokerscould be included if smoking not more than 10 cigarettes per day. 
 
In both studies, NAT2 phenotyping was carried out using a urine sample collected 4-6 hours 
after a 150 mg caffeine test. Caffeine metabolites were quantified by LC-MS/MS, and the 
molar ratio of caffeine metabolites (AFMU + AAMU)/ (AFMU+AAMU+ 1X+1U) (for 
abbreviations, see legend to Fig. 1) was used as a validated NAT2 metric [11]. Based on 
maximum log likelihood analysis, individuals with a ratio below 0.23 were classified as slow 
acetylators, those with values above 0.26 were considered as rapid acetylators (Fig. 1). Those 
with intermediate values were rated as “unclassified”.  
 
Individuals were studied under standardized conditions. Alcohol and grapefruit products were 
prohibited before and during the study. The volunteers had to remain in the Clinical 
Pharmacology ward from the evening prior to dosing at the profiling days until withdrawal of 
the last sample.  
 
In study A, no food intake was allowed from 8 hours before until 2 hours after each morning 
administration, from 2 hours before until 2 hours after each afternoon administration and from 
3.5 hours before until 8 hours after each late evening administration, with the exception of a 
snack given 10 min prior to each administration of the study medication. Standardized meals 
were given 12 hours prior to and 2 and 5 hours after the last mesalazine dose on the profiling 
day. In study B, subjects were fasting from 10 hours prior to mesalazine administration until 6 
 
Lück et al: Mesalazine and NAT2 page 6 
 
hours thereafter, and they adhered to supine position for 6 hours postdose. Meals were given 
6, 9, 12 and 16 hours after mesalazine administration. The generally allowed fluid intake was 
1.8 to 2.0 liters daily. In both studies, no fluid intake additional to that provided for drug 
intake (180 ml) was allowed from 2 hours before to 2 hours after drug intake. Thereafter, 120 
mg of water was administered every hour.  
 
Mesalazine doses were 1000 mg given as two 500 mg commercial prolonged release tablets 
(Pentasa®). In the multiple dose study A, this 1000 mg dose was given thrice daily for 5 days, 
and urine (0-4 and 4-8 hours postdose) and 17 blood samples were drawn in the last dosing 
interval. In the 1000 mg single dose study B, 21 blood samples were taken until 48 hours 
postdose, and urine was collected 0-4, 4-8, 8-12, 12-24, and 24-48 hours postdose.  
 
Plasma and urine samples of mesalazine and N-acetylmesalazine were analyzed by validated 
LC-MS/MS assays. For mesalazine, plasma samples (0.1 mL) were precipitated by addition 
of 200 µL of acetonitrile containing the internal standard. After thorough mixing, the samples 
were centrifuged for 10 minutes at 3,280 g at approximately +4 °C, and the supernatant was 
diluted (1:4) with ammonium acetate buffer. 60 µL of each sample were chromatographed on 
a reversed-phase column (Nucleosil 100-5 Protect 1), eluted with an isocratic solvent system 
consisting of ammonium acetate (pH 3.5) buffer and acetonitrile (75/25,v/v) and monitored by 
LC-MS/MS with a SRM method as follows: Precursor → product ion for mesalazine m/z 152 
→ m/z 108 and m/z 266 → m/z 223 for internal standard, all analyses were in negative mode. 
Under these conditions mesalazine and the internal standard were eluted after approximately 
1.5 and 1.6 minutes, respectively. The MacQuan software (version 1.6, PE Sciex, Thornhill, 
Ontario, Canada, 1991 - 1998) was used for evaluation of chromatograms. Urine samples 
were thawed, and stored for 20 minutes at 37 °C. 0.02 mL of each sample were diluted using 
1.98 mL of mobile phase containing the internal standard. After thorough mixing, the samples 
were stored for 10 minutes at 37 °C. 25 µL of each sample were chromatographed as 
described above. There was no interference observed in plasma or urine for mesalazine or the 
internal standard. Weighted linear regression (1/concentration) was performed for calibration 
in human plasma and urine. Linearity of the calibration could be proven in human plasma 
between 0.0493 µg/mL and 4.89 µg/mL (Study A and B) and in human urine between 0.953 
and 97.9 µg/mL for Study A and between 0.251 to 60.1 µg/mL for Study B. Lower limit of 
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quantification were identical with the lowest calibration levels. The inter-day precision of 
mesalazine in human plasma ranged from 6.0 to 8.3 % with an analytical recovery between 
99.3 % and 102.2 %. The inter-day precision of the spiked quality control standards of 
mesalazine in human urine ranged from 6.4 to 14.3 % with an analytical recovery between 
97.6 and 107.5 % for Study B. For N-acetyl mesalazine preparation of the human plasma and 
urine samples see mesalazine. Thereafter, human plasma (35 µL) and urine (25 µL) samples 
were chromatographed on a reversed-phase column (Waters Symmetry Shield C-8), eluted 
with an isocratic solvent system consisting of ammonium acetate (pH 3.5) buffer and 
acetonitrile (70/30,v/v) and monitored by LC-MS/MS with a SRM method as follows: 
Precursor → product ion for N-acetyl mesalazine m/z 194 → m/z 150 and m/z 266 → m/z 
223 for internal standard, all analyses were in negative mode. Under these conditions N-acetyl 
mesalazine and the internal standard were eluted after approximately 1.4 and 0.9 minutes, 
respectively. The MacQuan software (version 1.6, PE Sciex, Thornhill, Ontario, Canada, 1991 
- 1998) was used for evaluation of chromatograms. There was no interference observed in 
plasma or urine, for N-acetyl mesalazine or the internal standard. Weighted linear regression 
(1/concentration) was performed for calibration. Linearity of the calibration could be proven 
in human plasma between 0.0497 µg/mL and 4.94 µg/mL (Study A and B) and in human 
urine between 0.956 and 98.2 µg/mL for Study A and between 2.00 and 100 µg/mL for Study 
B. Lower limit of quantification were identical with the lowest calibration levels. Ihe inter-
day precision of N-acetyl mesalazine in human plasma ranged from 6.3 to 9.1 % with an 
analytical recovery between 98.3 and 103.4 %. The inter-day precision of the spiked quality 
control standards of N-acetyl mesalazine in human urine ranged from 2.4 to 10.4 % with an 
analytical recovery between 95.3 and 111.0 %. 
 
Pharmacokinetic parameters were calculated by noncompartmental methods (WinNonlin 2.0, 
Pharsight Corporation, Palo Alto, U.S.A.). Statistical evaluations are considered as 
descriptive. Mesalazine pharmacokinetics were compared between acetylator groups by the t-
test for independent samples. The relationship of mesalazine kinetics vs. NAT2 activity was 
further examined by linear regression (SPSS 15.0 for Windows, SPSS Inc., Chicago, U.S.A.). 
For metabolic ratios, AUC, Cmax and Ae, a multiplicative model was assumed, and 
geometric instead of arithmetic means and ratios instead of differences were calculated by ln 
transformation of the data prior to analysis and respective back-transformation thereafter.  
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RESULTS 
The frequency distribution of NAT2 activities is shown in Fig. 1. Overall, 30 rapid and 13 
slow acetylators were identified. Concentration vs. time profiles for both mesalazine and N-
acetylmesalazine are depicted in Fig. 2 and 3. Irregular profiles and persisting low 
concentrations of mesalazine at the final part of some profiles precluded a reliable calculation 
of apparent elimination half lives; thus, these are not reported, and extrapolation of AUC was 
not done.  
 
Concentration vs. time plots are presented separately for slow and rapid acetylators of the 
multiple dose study (Fig. 2) and the single dose study (Fig. 3), main pharmacokinetic 
parameters with relevance for the rate and extent of metabolism are presented in Table 1. 
There is pronounced interindividual variability in the profiles and the respective parameters, 
which is even higher in the single dose study. Considerably higher AUC values for 
mesalazine at steady state study indicate saturation of mesalazine metabolism. This is also 
reflected by less than 0.3 % of a mesalazine dose being excreted unchanged in the single dose 
study while roughly 9 % of the doses were excreted unchanged in the multiple dose study 
(Table 1).  
 
There is no evidence for a true difference in mesalazine pharmacokinetics between slow and 
rapid acetylators. The plots do not show clear differences between NAT2 phenotypes (Fig. 2, 
3). Only for one parameter out of 25, a statistically significant difference (p<0.05) was 
observed, and this one does not support a more rapid metabolism of mesalazine in NAT2 
rapid acetylators. There was no overlapping of 95 % CIs for the comparison between 
acetylator phenotypes between the NAT2 metric and any mesalazine parameter in the 
multiple dose study, and only marginal overlapping for a few parameters in the single dose 
study (Tab. 1). Also, there was no significant correlation between NAT2 phenotype and any 
of the mesalazine pharmacokinetic parameters (for AUC values, see Fig. 4).  
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DISCUSSION 
 
In this evaluation, pharmacokinetics of mesalazine were compared between slow and rapid 
acetylators for NAT2 both in a single dose and a multiple dose study as acetylation is 
saturated during chronic administration. Our results do not provide evidence for a major role 
for NAT2 in the metabolism of mesalazine in vivo.  
 
Traditionally, NAT2 phenotypes were described as “slow” or “rapid” acetylators; however, 
depending on the number of NAT2 alleles coding for a highly active enzyme variant (i.e. 0, 1 
or 2, respectively), three groups of individuals with respect to acetylation rate of individual 
NAT2 substrates may be discerned [12], although statistical analysis usually fails to identify 
more than two groups based on pharmacokinetic parameters. In the present study, 30 % of 
classifiable individuals were allocated to the slow acetylator phenotype, which is lower than 
the 50 % of Caucasians reported to have two low-activity alleles [13]. Thus, the allocation to 
“slow” and “rapid” acetylator phenotype may represent some ambiguity with regard to NAT2 
genotype. However, the caffeine metabolic ratio used here as the NAT2 metric has been 
validated extensively [11 and references therein]. From 4 hours after dosing on, this ratio 
remains unchanged for at least another 12 hours and thus is robust against deviations in urine 
sampling [14]. Therefore, the results of NAT2 phenotyping are considered as reliable from 
both a scientific and technical point of view and, as for any valid phenotyping procedure, may 
provide information beyond genotyping [15]. It should be mentioned that the metabolic 
caffeine ratio has been shown to reflect the activity of hepatic NAT2 [16], but activity 
differences between NAT2 genotypes most probably also apply to intestinal tissue [17].  
 
Pharmacokinetic parameters of mesalazine observed here are similar to those reported, 
including saturation of acetylation for chronic administration [1, 18]. Because of the short 
elimination half-life of mesalazine of clearly less than 3 hours [1, 7], a prolonged release 
preparation is needed for maintaining plasma concentrations during a dosing interval, but also 
for direct delivery to any intestinal site of action. Mesalazine release from this formulation 
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has been reported to occur throughout the gastrointestinal tract [19]. It has a bioavailability of 
approximately 30 % [18] which is lower than that of gastroresistant tablets and may be in part 
be caused by a more extensive intestinal first pass metabolism which is saturable [7] (see also 
Table 1). Indeed, in vitro studies showed that homogenates of colonic mucosa [8] and more 
specifically the cytosol of human colonic epithelial cells are able to mediate mesalazine N-
acetylation [20].  
 
The current evaluation was done within the framework of bioequivalence studies, which had 
not been powered explicitly to assess the role of NAT2 phenotype in mesalazine 
pharmacokinetics. Because the limited number of individuals and the pronounced 
interindividual variation in mesalazine pharmacokinetics, we are not able to exclude an effect 
of NAT2 genotype on mesalazine acetylation in vivo. However, the 95 % CIs for the 
comparison between phenotypes clearly show that if there were any differences in mesalazine 
kinetics between acetylator phenotyes, they would be much smaller than differences in 
enzyme activity. In contrast, for isoniazid as a known NAT2 substrate, pharmacokinetic 
differences fully reflect differences in enzyme activity [12]. Thus, our data show that NAT2 
has no major – if any – role in human metabolism of mesalazine in vivo. As NAT2 (and 
NAT1) polymorphisms have also no influence on inflammatory bowel disease by itself [21], 
there is no rationale to consider NAT2 activity in the treatment with mesalazine.  
 
It is still desirable to identify sources for variability in mesalazine pharmacokinetics other 
than NAT2 polymorphism. Obviously, intestinal liberation rate of the drug from the 
preparation may contribute. Furthermore, there is clear role of bacterial NAT in overall N-
acetylation of mesalazine, albeit its magnitude is controversial [22, 23]. Also, the reported 
lack of differences in mesalazine response and tolerability between NAT1 genotypes [9, 10] 
does not exclude differences in mesalazine pharmacokinetics, because differences in activity 
in NAT1 variants are limited [24, 25] and pharmacodynamic parameters are less sensitive 
than pharmacokinetic parameters. Finally, in patients the degree of intestinal inflammation 
affects mesalazine pharmacokinetics [26]. Further research is needed to improve our 
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understanding of the fate of mesalazine in the human body in order to assess a rationale for 
individual dose optimisation, with the chance to improve the risk/benefit ratio of this drug and 
maybe also to to reduce the risk for rare adverse effects such as interstitial nephritis [27]. 
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TABLES 
 
Table 1: Pharmacokinetic parameters of mesalazine (arithmetic means ± SD or geometric 
means [% CV]) and the respective comparison for rapid acetylators relative to slow 
acetylators (difference or ratio [95 % CI]) following oral administration of 1000 mg doses 
parameter Point estimates and  
metric of variability 
Comparison rapid 
vs. slow acetylators 
Study A (multiple dose) 
acetylator phenotype  slow rapid - 
number classifiable      21 5 n.a. 
NAT2 metric#  0.086 [58 %] 0.299 [13 %]** 3.49 [2.26 – 5.39] 
sex (n male / female) 16 m / 5 f 3 m / 2 f n.a. 
age (years) 26.0 ± 4.3 27.8 ± 2.0 1.8 [-2.3 – 6.0] 
body weight (kg) 73.0 ± 10.8 72.4 ± 10.1 -0.7 [-11.7 – 10.3] 
body height (cm) 179 ± 8 175 ± 10 -4 [-13 – 5] 
mesalazine AUCτ (0-8h) (µg/mL*h)       11.1 [51 %] 12.0 [52 %] 1.08 [0.71 – 1.65] 
N-acetylmesalazine AUCτ (0-8h) (µg/mL*h)       27.7 [32 %] 30.5 [27 %] 1.10 [0. 83 – 1.46] 
AUCτ (0-8h) ratio N-acetylmesalazine / mesalazine 2.49 [28 %] 2.54 [38 %] 1.02 [0. 78 – 1.33] 
mesalazine Cssmax (µg/mL)       3.00 [57 %] 3.48 [60 %] 1.16 [0. 73 – 1.85] 
N-acetylmesalazine Cssmax (µg/mL)       5.71 [51 %] 7.13[47 %] 1.25 [0. 82 – 1.90] 
Cssmax ratio N-acetylmesalazine / mesalazine 1.91 [35 %] 2.05 [48 %] 1.07 [0. 77 – 1.49] 
mesalazine Ae 0-8h (% of dose)         8.53 [89 %] 9.03 [52 %] 1.06 [0. 57 – 1.97] 
N-acetylmesalazine Ae 0-8h (% of dose)        31.4 [46 %] 32.2 [41 %] 1.03 [0. 70 – 1.51] 
Ae 0-8h ratio N-acetylmesalazine / mesalazine 3.68 [74 %] 3.57 [32 %] 0.97 [0. 57 – 1.65] 
mesalazine tssmax (h)       2.15 ± 0.57 2.30 ± 0.27 0.15 [-0.40 – 0.70] 
N-acetylmesalazine tssmax (h)       2.69 ± 0.75 2.70 ± 0.45 0.01 [-0.72 – 0.73] 
Study B (single dose) 
acetylator phenotype  slow rapid - 
number classifiable      9 8 n.a. 
NAT2 metric# 0.150 [18 %] 0.370 [28 %]** 2.46 [1.98-3.05] 
sex (n male / female) 5 m / 4 f 7 m / 1 f n.a. 
age (years) 25.2 ± 2.5 26.6 ± 4.2 1.4 [-2.1 – 4.9] 
body weight (kg) 74.4 ± 14.1 74.1 ± 4.8 -0.3 [-11.8 – 10.9] 
body height (cm) 179 ± 8 179 ± 6 0 [-8 – 7] 
mesalazine AUC0-48h (µg/mL*h)       3.45 [113 %] 2.36 [87 %] 0.68 [0.33 – 1.41] 
N-acetylmesalazine AUC0-48h (µg/mL*h)       21.3 [29 %] 18.0 [39 %] 0.84 [0. 62 – 1.14] 
AUC0-48h ratio N-acetylmesalazine / mesalazine 6.18 [112 %] 7.63 [69 %] 1.23 [0. 63 – 2.43] 
mesalazine Cmax (µg/mL)       0.81 [104 %] 0.82 [147] 1.01 [0. 44 – 2.32] 
N-acetylmesalazine Cmax (µg/mL)       2.40 [61 %] 1.67 [73 %] 0.69 [0. 41 – 1.18] 
Cmax ratio N-acetylmesalazine / mesalazine 2.95 [110 %] 2.03 [89 %] 0.69 [0. 34 – 1.42] 
mesalazine Ae0-48h (% of dose)         0.2 [256 %] 0.1 [359 %] 0.42 [0. 10 – 1.80] 
N-acetylmesalazine Ae0-48h (% of dose)         30.9 [44 %] 18.1 [84 %]* 0.59 [0. 35 – 0.98] 
Ae 0-48h ratio N-acetylmesalazine / mesalazine 138 [259 %] 190 [308 %] 1.38 [0. 34 – 5.52] 
mesalazine tmax (h)       3.39 ± 1.64 2.70 ± 1.51 -0.69 [-2.33 – 0.94] 
N-acetylmesalazine tmax (h)       2.89 ± 2.33 3.25 ± 1.79 0.36 [-1.81 – 2.53] 
mesalazine half value duration (h)       3.60 ± 1.60 2.22 ± 1.25 -1.39 [-2.88 – 0.11] 
N-acetylmesalazine half value duration (h)       6.10 ± 2.89 6.65 ± 3.85 0.54 [-2.95 – 4.03] 
#urinary caffeine metabolic ratio (AFMU+AAMU)/ (AFMU+AAMU+1X+1U); *p<0.05; 
**p<0.00001< n.a., not applicable 
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FIGURES 
 
Figure 1: Relative Frequency Distribution of NAT2 activities 
 
Individuals with a caffeine metabolic ratio below 0.23 were classified as slow acetylators, 
those with a ratio above 0.26 were considered as rapid acetylators. 1X, 1-methylxanthine; 1U, 
1-methyluric acid; AFMU, 5-acetylamino-6-formylamino-3-methyluracil; AAMU, 5-
acetylamino-6-amino-3-methyluracil.  
 
 
0
5
10
15
20
25
st
ud
y 
A 
(%
)
5
10
15
20
25
st
ud
y 
B
 (%
)
0.0 0.1 0.2 0.3 0.4 0.5 0.6
caffeine metabolic ratio (AFMU+AAMU)/(AFMU+AAMU+1X+1U)
slow acetylators                                          rapid acetylators
"u
nc
la
ss
fie
d"
 ra
ng
e
 
 
 
Lück et al: Mesalazine and NAT2 page 14 
 
Figure 2: Individual and mean + SD mesalazine (upper part) and N-acetylmesalazine (lower 
part) concentration vs. time profiles in the last dosage interval following multiple dose 
administration of 1000 mg mesalazine thrice daily for 5 days (study A)  
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Figure 3: Individual and mean + SD mesalazine (upper part) and N-acetylmesalazine (lower 
part) concentration vs. time profiles following administration of a 1000 mg mesalazine single 
dose (study B) 
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Figure 4: Relationship of mesalazine and N-acetylmesalazine AUC to NAT2 activity  
There was no significant correlation of AUC values calculated separately for studies A and B, 
respectively, and the caffeine NAT2 metabolic ratio. 1X, 1-methylxanthine; 1U, 1-methyluric 
acid; AFMU, 5-acetylamino-6-formylamino-3-methyluracil; AAMU, 5-acetylamino-6-amino-
3-methyluracil. 
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